{
    "clinical_study": {
        "@rank": "26754", 
        "arm_group": [
            {
                "arm_group_label": "Fenofibrate", 
                "arm_group_type": "Experimental", 
                "description": "Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo oral tablets daily for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Long-standing type 1 diabetes is often complicated by retinopathy. The mechanisms that\n      induce the development of diabetic retinopathy are incompletely understood and include\n      alterations in bone marrow derived vasculogenic cells called \"endothelial progenitor cells\".\n\n      Fenofibrate is a PPAR-alpha agonist used for the treatment of mixed dislipidemia and\n      hypertriglyceridemia. In a trial conducted in type 2 diabetic patients, the drug fenofibrate\n      has reduced retinopathy-related endpoints suggesting a direct effect of the drug on the\n      mechanisms that drive the development of this complication.\n\n      Herein, the investigators hypothesize that fenofibrate treatment can increase circulating\n      EPC levels in type 1 diabetic patients with retinopathy, compared to placebo."
        }, 
        "brief_title": "Effects of Fenofibrate on Endothelial Progenitor Cells in Type 1 Diabetes", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 1 Diabetes", 
            "Diabetic Retinopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetic Retinopathy", 
                "Retinal Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Long-standing type 1 diabetes is often complicated by retinopathy. The mechanisms that\n      induce the development of diabetic retinopathy are incompletely understood and include\n      alterations in bone marrow derived vasculogenic cells called \"endothelial progenitor cells\".\n\n      Fenofibrate is a PPAR-alpha agonist used for the treatment of mixed dislipidemia and\n      hypertriglyceridemia. In addition to lowering triglyceride-rich lipoproteins, PPAR-alpha\n      agonism with fenofibrate has several additional molecular benefit on the vessel wall, such\n      as reduction of inflammation. In a trial conducted in type 2 diabetic patients, the drug\n      fenofibrate has reduced retinopathy-related endpoints suggesting a direct effect of the drug\n      on the mechanisms that drive the development of this complication.\n\n      Preliminary data of ours on the effects of fenofibrate on cultured EPC show that this drug\n      has the potential to improve EPC and, consequently, may benefit patients with retinopathy.\n\n      Herein, the investigators hypothesize that fenofibrate treatment can increase circulating\n      EPC levels in type 1 diabetic patients with retinopathy, compared to placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Moderate/Severe retinopathy\n\n          -  Age 18-65\n\n          -  Both sexes\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes\n\n          -  Age <18 or >65\n\n          -  Statin therapy\n\n          -  Hereditary muscle disorders\n\n          -  Uncontrolled hypothyroidism\n\n          -  Elevated alcohol consumption\n\n          -  Renal failure\n\n          -  Hepatic failure\n\n          -  Allergy to fenofibrate or excipients\n\n          -  Acute / chronic pancreatitis\n\n          -  Pregnancy and lactation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927315", 
            "org_study_id": "2871P"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fenofibrate", 
                "description": "Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.", 
                "intervention_name": "Fenofibrate 145 mg", 
                "intervention_type": "Drug", 
                "other_name": "Fulcrosupra 145 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Oral Placebo tablets once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo control"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fenofibrate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Stem cells", 
            "Regeneration", 
            "Angiogenesis", 
            "Prevention"
        ], 
        "lastchanged_date": "August 21, 2013", 
        "location": {
            "contact": {
                "email": "gianpaolo.fadini@unipd.it", 
                "last_name": "Gian Paolo Fadini, MD PhD", 
                "phone": "0039 049 8214318"
            }, 
            "facility": {
                "address": {
                    "city": "Padova", 
                    "country": "Italy", 
                    "zip": "35100"
                }, 
                "name": "University Hospital of Padova, Diabetes Outpatient Clinic"
            }, 
            "investigator": [
                {
                    "last_name": "Gian Paolo Fadini, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Alberto Zambon, MD PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Type 1 Diabetic Patients With Retinopathy. A Randomized Controlled Trial.", 
        "overall_contact": {
            "email": "gianpaolo.fadini@unipd.it", 
            "last_name": "Gian Paolo Fadini, MD PhD", 
            "phone": "0039 049 8214318"
        }, 
        "overall_official": {
            "affiliation": "University of Padova", 
            "last_name": "Gian Paolo Fadini, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in endothelial progenitor cell (EPC) levels in fenofibrate-treated vs placebo-treated patients over 12 weeks.", 
            "measure": "Endothelial progenitor cells", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change in oxLDL levels in fenofibrate-treated vs placebo-treated patients over 12 weeks.", 
            "measure": "Oxidized LDL", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "University of Padova", 
        "sponsors": {
            "collaborator": {
                "agency": "Azienda Ospedaliera di Padova", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Padova", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}